Uckun FM - Search Results

1

Evaluation of the potential of Rejuveinix plus dexamethasone against sepsis.

Uckun FM, Saeed M, Awili M, Ozercan IH, Qazi S, Lee C, Shibli A, Skolnick AW, Prusmack A, Varon J, Barrera CI, Orhan C, Volk M, Sahin K. Uckun FM, et al. Future Microbiol. 2022 Oct;17:1217-1229. doi: 10.2217/fmb-2022-0044. Epub 2022 Sep 2. Future Microbiol. 2022. PMID: 36052743 Free PMC article.

2

Chemopreventive efficacy of stampidine in a murine breast cancer model.

Sahin K, Orhan C, Ozercan IH, Tuzcu M, Elibol B, Sahin TK, Kilic U, Qazi S, Uckun FM. Sahin K, et al. Among authors: uckun fm. Expert Opin Ther Targets. 2020 Feb;24(2):155-162. doi: 10.1080/14728222.2020.1724961. Epub 2020 Feb 5. Expert Opin Ther Targets. 2020. PMID: 32005098 Free PMC article.

3

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.

Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A, Shami PJ, Cull E, Cogle CR, Watts J. Uckun FM, et al. Cancers (Basel). 2021 Aug 15;13(16):4113. doi: 10.3390/cancers13164113. Cancers (Basel). 2021. PMID: 34439266 Free PMC article.

4

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436.

Uckun FM, Watts J, Mims AS, Patel P, Wang E, Shami PJ, Cull E, Lee C, Cogle CR, Lin TL. Uckun FM, et al. Cancers (Basel). 2021 Oct 21;13(21):5287. doi: 10.3390/cancers13215287. Cancers (Basel). 2021. PMID: 34771451 Free PMC article.

5

Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61.

Sahin TK, Aktepe OH, Uckun FM, Yalcin S. Sahin TK, et al. Among authors: uckun fm. Anticancer Drugs. 2020 Jul;31(6):609-616. doi: 10.1097/CAD.0000000000000910. Anticancer Drugs. 2020. PMID: 32044796

6

SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research.

Guven DC, Sahin TK, Akın S, Uckun FM. Guven DC, et al. Among authors: uckun fm. Oncologist. 2022 Nov 3;27(11):e917-e918. doi: 10.1093/oncolo/oyac173. Oncologist. 2022. PMID: 36005823 Free PMC article.

7

Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.

Guven DC, Sahin TK, Akın S, Uckun FM. Guven DC, et al. Among authors: uckun fm. Oncologist. 2022 Apr 5;27(4):e357-e361. doi: 10.1093/oncolo/oyac032. Oncologist. 2022. PMID: 35274729 Free PMC article.

8

COVID-19 pandemic: changes in cancer admissions.

Guven DC, Aktas BY, Aksun MS, Ucgul E, Sahin TK, Yildirim HC, Guner G, Kertmen N, Dizdar O, Kilickap S, Aksoy S, Yalcin S, Turker A, Uckun FM, Arik Z. Guven DC, et al. Among authors: uckun fm. BMJ Support Palliat Care. 2020 Jul 14:bmjspcare-2020-002468. doi: 10.1136/bmjspcare-2020-002468. Online ahead of print. BMJ Support Palliat Care. 2020. PMID: 32665259

9

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma.

Uckun FM. Uckun FM. Cancers (Basel). 2021 Apr 22;13(9):2018. doi: 10.3390/cancers13092018. Cancers (Basel). 2021. PMID: 33922005 Free PMC article. Review.

10

Cancer drug resistance in multiple myeloma.

Uckun FM. Uckun FM. Cancer Drug Resist. 2022 Mar 25;5(2):271-276. doi: 10.20517/cdr.2022.32. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35800374 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

534 results

Search Page